Theralase Technologies ( (TSE:TLT) ) just unveiled an update.
Theralase Technologies has announced promising interim clinical data showing that their TLC-2400 Cool Laser Therapy system improves motor and non-motor functions in patients with Parkinson’s Disease. This development could significantly impact the treatment landscape for Parkinson’s, a prevalent neurodegenerative disorder, by offering a non-invasive option that enhances neuromotor function through dopamine production.
More about Theralase Technologies
Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research and development of light, radiation, sound, and drug-activated small molecules for the treatment of cancers, bacteria, and viruses.
YTD Price Performance: -5.45%
Average Trading Volume: 108,712
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$64.42M
For an in-depth examination of TLT stock, go to TipRanks’ Stock Analysis page.